Viewing Study NCT03708003

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:25 PM
Ignite Modification Date: 2026-02-13 @ 10:27 AM
Study NCT ID: NCT03708003
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-27
First Post: 2018-10-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Sponsor: Swiss Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory Chronic Lymphocytic Leukemia View
None Chronic Lymphocytic Leukemia View
None Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None lymphocytic leukemia View
None relapsed/refractory chronic lymphocytic leukemia View
None Ibrutinib View
None venetoclax View